ESR1 and breast carcinoma: In prior studies in an estrogen receptor negative (ER-) model of breast cancer, we demonstrated that CDDO-Me alters immune activation in the TME and redirects TAM activation from immunosuppressive to immunostimulatory (10, 11), To determine if CDDO-Me mediates similar effects in melanoma, human peripheral blood-derived monocytes were co-cultured for 7 days with SK-MEL-28 melanoma cells harboring the BRAFV600E mutation using Transwells (Figure 1A).